Enclomiphene Overview, Dosing & Safety | Peptide Database

Enclomiphene (Androxal)

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Community Research

Join others researching Enclomiphene — share findings, ask questions, and learn from real experiences

Enclomiphene is the trans-isomer of clomifene citrate, a selective estrogen receptor modulator (SERM) that acts primarily as an estrogen antagonist at the hypothalamus and pituitary. Unlike the racemic mixture clomifene (Clomid), which contains both enclomiphene and the cis-isomer zuclomifene, enclomiphene lacks significant estrogenic agonist activity. This makes it better suited for raising endogenous testosterone through increased LH and FSH secretion without the estrogenic side effects commonly associated with clomifene. It was developed under the trade name Androxal for the treatment of secondary hypogonadism in men but has not yet received FDA approval as a standalone product.

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Elevated LH drives Leydig cell testosterone synthesis in the testes, while FSH supports Sertoli cell function and spermatogenesis. Because enclomiphene lacks the estrogenic agonist properties of zuclomifene, it provides cleaner HPTA stimulation without paradoxical estrogenic effects on mood, vision, or other tissues.

Molecular Data

Research Indications

Restores endogenous testosterone production in men with secondary hypogonadism by increasing LH and FSH through hypothalamic estrogen receptor antagonism. Phase III trials demonstrated significant testosterone normalization.

Provides a non-suppressive alternative to exogenous testosterone for men seeking to raise testosterone levels while maintaining natural HPTA function and fertility.

Can serve as a standalone alternative to testosterone replacement therapy in appropriate candidates, particularly younger men or those concerned about fertility preservation.

Accelerates recovery of the hypothalamic-pituitary-testicular axis after suppression from anabolic steroids or exogenous testosterone by rapidly increasing LH and FSH output.

Helps restore natural testosterone production to baseline levels faster than unassisted recovery, reducing the hypogonadal window after cycle cessation.

FSH elevation driven by enclomiphene supports Sertoli cell function and spermatogenesis, making it useful for men with oligospermia associated with secondary hypogonadism.

Can be used as a bridge off TRT for men who wish to conceive, maintaining testosterone levels while restoring spermatogenesis.

Dosing Protocols

Enclomiphene is administered orally as a capsule or tablet. It is well absorbed with consistent bioavailability. Take at the same time each day, with or without food. Morning dosing is generally preferred to align with natural hormonal rhythms.

Testosterone restoration (conservative start)

12.5mg

Once daily

Oral

Testosterone restoration (standard)

25mg

Post-cycle therapy (standard)

Once daily for 4-8 weeks

Post-cycle therapy (aggressive)

50mg

Once daily for 4-6 weeks

Long-term hypogonadism management

12.5-25mg

Once daily (ongoing with monitoring)

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Headache

Nausea or mild gastrointestinal discomfort

Hot flashes or flushing

Mood changes (irritability or emotional sensitivity)

Fatigue during initial adjustment

Stop Signs - Discontinue if:

Severe or persistent visual changes (flashes, blurred vision, scotomata)

Signs of blood clots (leg swelling, chest pain, shortness of breath)

Persistent severe headaches unresponsive to common analgesics

Significant mood disturbances or depression

Jaundice or signs of liver dysfunction

Contraindications

Known hypersensitivity to clomifene or enclomiphene

Pre-existing liver disease or significantly elevated liver enzymes

Active or history of thromboembolic disorders

Pregnancy or women who may become pregnant (teratogenic risk)

Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)

Pituitary tumors or undiagnosed pituitary pathology

Quality Checklist

Good Signs

White to off-white crystalline powder or uniform capsules/tablets

Third-party certificate of analysis (COA) confirming identity and purity (>98%)

HPLC testing verifying enclomiphene (trans-isomer) without significant zuclomifene contamination

Professional packaging with batch number, expiration date, and proper labeling

Sourced from a licensed compounding pharmacy or reputable research supplier

Warning Signs

No COA or third-party testing available

Product labeled as 'clomifene' or 'clomiphene' rather than specifically 'enclomiphene' (may be racemic mixture)

Inconsistent capsule fill weight or tablet appearance

Bad Signs

Discolored, clumped, or visibly degraded powder

Unusual chemical odor

No labeling, batch information, or expiration date

COA shows significant zuclomifene (cis-isomer) contamination indicating racemic product sold as enclomiphene

Sourced from unverified vendors with no quality documentation

Frequently Asked Questions

Is enclomiphene better than clomiphene (Clomid) for PCT?

Enclomiphene is the pure trans-isomer while clomiphene (Clomid) is a racemic mixture containing both enclomiphene and zuclomifene (the cis-isomer). Zuclomifene has significant estrogenic agonist activity, which can cause mood issues, visual disturbances, and other estrogenic side effects. Enclomiphene lacks these estrogenic effects because it is pure trans-isomer. In terms of raising LH/FSH and testosterone for PCT, both work similarly, but enclomiphene has a cleaner side effect profile. However, enclomiphene is not FDA-approved and is harder to source, whereas clomiphene is widely available. If you can access verified enclomiphene, it is the better choice; otherwise, clomiphene works for PCT.

Can I use enclomiphene as an alternative to testosterone replacement therapy?

Yes, enclomiphene can be a viable alternative for men with secondary hypogonadism who wish to maintain natural testosterone production and fertility. Unlike exogenous testosterone which shuts down the HPTA axis and causes testicular atrophy, enclomiphene stimulates endogenous testosterone production through LH/FSH stimulation while preserving sperm production. Clinical trials show enclomiphene raises testosterone into the normal range at 12.5-25mg daily. The downside is that enclomiphene generally produces slightly lower testosterone levels than TRT, it requires consistent compliance, and it is not available through standard pharmacies. It works best for younger men or those specifically concerned about fertility preservation.

How fast does enclomiphene raise testosterone after a steroid cycle?

LH and FSH begin rising within 1-2 weeks. Serum testosterone starts increasing measurably by week 2-4. Most users see testosterone return to normal physiological range by week 4-6. This is significantly faster than unassisted HPTA recovery, which typically takes 8-12 weeks. The standard PCT protocol is 25-50mg daily for 4-8 weeks, with the aggressive approach (50mg for 4-6 weeks) used after heavy suppressive cycles. Bloodwork at weeks 4-6 and again 4 weeks post-PCT completion allows you to verify recovery and know when to come off the enclomiphene.

Does enclomiphene cause visual problems like Clomid does?

Visual disturbances are a known side effect of clomifene (Clomid) due to the zuclomifene cis-isomer's estrogenic agonist activity. Enclomiphene, being pure trans-isomer without zuclomifene, has a much lower incidence of visual problems. However, some rare cases of visual disturbances have been reported with enclomiphene, so it is not zero-risk. Most users tolerate it without any visual issues. If you develop vision changes (floaters, blurred vision, light sensitivity), discontinue immediately and seek medical evaluation. This is why enclomiphene is still preferred over racemic clomiphene when available.

References

Enclomiphene citrate 25mg daily raised total testosterone into the normal range while maintaining or improving sperm counts, in contrast to topical testosterone which suppressed spermatogenesis. Demonstrated enclomiphene as a viable alternative to TRT for secondary hypogonadism.

Comprehensive review of enclomiphene pharmacology and clinical trial data. Confirmed that enclomiphene normalizes testosterone, LH, and FSH in hypogonadal men while preserving sperm parameters. Highlighted its advantage over racemic clomifene due to absence of estrogenic agonist effects from zuclomifene.

In obese hypogonadal men, enclomiphene 25mg daily significantly increased total testosterone (mean from ~228 to ~420 ng/dL) while preserving sperm concentrations. Topical testosterone by contrast reduced sperm counts. Supports enclomiphene as a fertility-preserving alternative.

Review of SERMs including enclomiphene for male infertility. Confirmed that SERMs increase gonadotropins and testosterone through hypothalamic estrogen receptor blockade. Noted enclomiphene's advantage of pure anti-estrogenic activity without the mixed agonist/antagonist profile of clomifene.

Phase III trial review showing enclomiphene 12.5mg and 25mg daily both significantly increased total testosterone versus placebo in men with secondary hypogonadism. Mean testosterone increases were dose-dependent and sustained over 6 months. LH and FSH were also significantly elevated, confirming the hypothalamic mechanism of action.

Related Peptides

HCG directly stimulates Leydig cells via LH receptor agonism while enclomiphene increases endogenous LH/FSH. Combining both provides dual-pathway testicular stimulation, useful in PCT or fertility protocols.

Gonadorelin provides pulsatile GnRH stimulation to the pituitary while enclomiphene removes estrogenic negative feedback. The combination can amplify LH/FSH output beyond either agent alone.

Kisspeptin stimulates GnRH neurons upstream of the pituitary while enclomiphene blocks estrogen negative feedback. Mechanistically complementary for HPTA activation.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.